The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
First human dose (FHD) study of the oral transforming growth factor-beta receptor I kinase inhibitor LY2157299 in patients with treatment-refractory malignant glioma.
J. Rodon Ahnert
No relevant relationships to disclose
J. Baselga
No relevant relationships to disclose
E. Calvo
Research Funding - Lilly
J. Seoane
Research Funding - Lilly
I. Brana
No relevant relationships to disclose
E. Sicart
No relevant relationships to disclose
I. Gueorguieva
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
A. Cleverly
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
M. M. F. Lahn
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
S. Pillay
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
M. Holdhoff
No relevant relationships to disclose
J. O. Blakeley
No relevant relationships to disclose
M. A. Carducci
No relevant relationships to disclose